65 results on '"Raman, Rema"'
Search Results
2. The AUstralian multidomain Approach to Reduce dementia Risk by prOtecting brain health With lifestyle intervention study (AU‐ARROW): A study protocol for a single‐blind, multi‐site, randomized controlled trial
3. Views and perceptions of amyloid imaging in a preclinical Alzheimer’s disease trial
4. Racial and Ethnic Differences in Plasma Biomarker Eligibility in a Preclinical Alzheimer’s Disease Trial
5. Natural cubic splines for the analysis of Alzheimer’s trials
6. Overcoming Recruitment Challenges and Increasing Representation and Diversity of Participation in Early MCI Clinical Trials: The MIND Study Experience
7. Culturally‐informed Community‐engaged Efforts to Improve Inclusion and Engagement of Underrepresented Ethnocultural Populations in the Alzheimer’s Disease Neuroimaging Initiative 3 Study: The ADNI Diversity Task Force
8. Protective effects of sleep duration and physical activity on cognitive performance are influenced by β‐amyloid and brain volume but not tau burden among cognitively unimpaired older adults
9. Eligibility rates among racially and ethnically diverse US participants in Phase 2 and Phase 3 placebo‐controlled, double‐blind, randomized trials of lecanemab and elenbecestat in early Alzheimer's disease
10. Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease
11. The Institute on Methods and Protocols for Advancement of Clinical Trials for ADRD (IMPACT‐AD): An update after two years of conduct.
12. Diversity in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Lecanemab and Elenbecestat Early Alzheimer’s Disease Studies
13. Strategies for diverse participant recruitment to a preclinical Alzheimer’s Disease prevention trial: The AHEAD study
14. Prevalence and Associations of Frailty in Preclinical Alzheimer’s Disease
15. Improving generalizability and study design of Alzheimer's disease cohort studies in the United States by including under‐represented populations
16. The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease
17. Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium
18. Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium
19. Methodological challenges across WW‐FINGERS Studies: Impact of COVID‐19 pandemic on statistical design and analysis plans for multidomain RCTs
20. AHEAD 3‐45 study: Preliminary screening and baseline characteristics from a placebo‐controlled, double‐blind study evaluating lecanemab in participants with preclinical Alzheimer’s disease and elevated (A45 trial) and intermediate (A3 trial) amyloid
21. Individual patient data meta‐analysis assessing the adverse event profile of Alzheimer dementia randomized clinical trials
22. The screening and enrollment of underrepresented ethnoracial and educational populations in the Alzheimer's Disease Neuroimaging Initiative
23. Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial‐Ready Cohort study
24. AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer’s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial)
25. Study partner factors on cognitive function index scores among participants screened for the A4 study
26. U.S. POINTER (USA)
27. The anti‐amyloid treatment in asymptomatic Alzheimer’s disease (A4) study: Report of screening and recruitment characteristics of the Melbourne composite site
28. AU‐ARROW (Australia)
29. Alternatives to MMRM for preclinical Alzheimer’s clinical trials
30. World‐Wide FINGERS Network: A global approach to risk reduction and prevention of dementia
31. DT-02-03: OPEN LABEL EXTENSION RESULTS FROM A PHASE II/III TRIAL OF INTRANASAL INSULIN
32. O4-11-03: U.S. POINTER: STUDY DESIGN AND LAUNCH
33. FTS3-01-04: FINAL EFFICACY, SAFETY AND BIOMARKER RESULTS OF THE PHASE 2B/3 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED EARLY TRIAL OF ATABECESTAT IN PRECLINICAL ALZHEIMER'S DISEASE
34. A mixed‐methods study of cultural beliefs about dementia and genetic testing among Mexicans and Mexican‐Americans at‐risk for autosomal dominant Alzheimer’s disease
35. O1‐02‐05: PREDICTING AMYLOID BURDEN IN SCREENING FOR PRECLINICAL AD PREVENTION TRIALS
36. P4‐280: BRAIN AMYLOID BURDEN, SLEEP, AND CIRCADIAN REST/ACTIVITY RHYTHMS: SCREENING FINDINGS FROM A4 AND LEARN
37. O1‐02‐01: IMPACT OF DISCLOSING AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL RESEARCH PARTICIPANTS: THE A4 EXPERIENCE
38. P4‐341: THE COMPUTERIZED COGNITIVE COMPOSITE (C3) AND AMYLOID STATUS AMONG NORMAL OLDER ADULTS
39. P4‐321: TAU PET IN A4: PRELIMINARY REPORT
40. TD‐P‐016: DEEP LEARNING IN AUTOMATED CLASSIFICATION OF ADVERSE EVENTS IN CLINICAL STUDIES OF ALZHEIMER'S DISEASE
41. U.S. GERIATRIC INTERVENTION STUDY TO PREVENT COGNITIVE IMPAIRMENT AND DISABILITY (U.S.-FINGER)
42. [P4–007]: MACHINE LEARNING IN AUTOMATED CLASSIFICATION OF ADVERSE EVENTS IN CLINICAL STUDIES OF ALZHEIMER's DISEASE
43. Telephone Problem Solving Treatment for Active Duty Service Members with Mild Traumatic Brain Injury
44. F3-02-02: MODELING LONG-TERM DISEASE PROGRESSION WITH COVARIATES
45. P4-101: REGIONAL VARIATION IN ALZHEIMER'S DISEASE PROGRESSION IN A CLINICAL TRIAL SETTING
46. P4-174: COMPARING RECRUITMENT AMONG GEOGRAPHIC REGIONS IN MULTINATIONAL ALZHEIMER'S DISEASE CLINICAL TRIALS
47. Estimating long‐term multivariate progression from short‐term data
48. Accounting for functional loss in Alzheimer's disease and dementia with Lewy bodies: Beyond cognition
49. P3-369: Alzheimer's disease patients with adult child study partners are underrepresented in clinical trials and may experience slower cognitive decline
50. P3-406: Role of caregiver in subject's compliance with treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.